Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 740 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

ORIGINAL ARTICLE

Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis

Yassin Mohamed A, Soliman Ashraf T, De Sanctis Vincenzo, Abdelrahman Mohamed Osman, Aziz Bedair Elsaid M, AbdelGawad Manal

Year : 2014| Volume: 18| Issue : 4 | Page no: 546-551

   This article has been cited by
 
1 Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
Mohamed A. Yassin,Mohamed O. Abdel Rahman,Anas A. Hamad,Abdul Razzakh Poil,Mohamed T. Abdelrazek,Radwa M. Hussein,Nancy A. Kassem,Afraa M. Fadul,Sarah A. Elkourashy,Abdulqadir J. Nashwan
Medicine. 2020; 99(51): e23637
[Pubmed]  [Google Scholar] [DOI]
2 Spinal cord compression due to extramedullary hematopoiesis in patient with Beta thalassemia major
Eihab A. Subahi,Mohamed Abdelrazek,Mohamed A. Yassin
Clinical Case Reports. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 A Rare Case of Hemoglobin E/Beta-Thalassemia and Systemic Lupus Erythematosus
Ibrahim Khamees,Ibrahim Mohammad Obeidat,Waail Rozi,Mohamed A Yassin
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
4 Management of age-associated medical complications in patients with -thalassemia
Irene Motta,Marta Mancarella,Alessia Marcon,Marco Vicenzi,Maria Domenica Cappellini
Expert Review of Hematology. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
5 Off-label uses of denosumab in metabolic bone diseases
Stergios A. Polyzos,Polyzois Makras,Symeon Tournis,Athanasios D. Anastasilakis
Bone. 2019; : 115048
[Pubmed]  [Google Scholar] [DOI]
6 Rheumatic Manifestations of Haemoglobinopathies
Michael Hughes
Current Rheumatology Reports. 2018; 20(10)
[Pubmed]  [Google Scholar] [DOI]
7 Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial
Ersi Voskaridou,Ioannis Ntanasis-Stathopoulos,Athanasios Papaefstathiou,Dimitrios Christoulas,Maria Dimopoulou,Konstantina Repa,Athanasios Papatheodorou,Melpomeni Peppa,Evangelos Terpos
Blood Advances. 2018; 2(21): 2837
[Pubmed]  [Google Scholar] [DOI]
8 Denosumab for the treatment of osteoporosis
Michael R. McClung
Osteoporosis and Sarcopenia. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Bone disease in thalassemia patients: past, present and future perspectives
Vincenzo De Sanctis,Ashraf T. Soliman,Heba Elsefdy,Nada Soliman,Elsaid Bedair,Bernadette Fiscina,Christos Kattamis
Metabolism. 2017;
[Pubmed]  [Google Scholar] [DOI]
10 Clinical Complications and Their Management
Alessia Marcon,Irene Motta,Ali Taher,Maria Domenica Cappellini
Hematology/Oncology Clinics of North America. 2017;
[Pubmed]  [Google Scholar] [DOI]
11 Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease
A. D. Dede,G. Trovas,E. Chronopoulos,I. K. Triantafyllopoulos,I. Dontas,N. Papaioannou,S. Tournis
Osteoporosis International. 2016;
[Pubmed]  [Google Scholar] [DOI]
12 Management of beta-thalassemia-associated osteoporosis
Andrea Giusti,Valeria Pinto,Gian Luca Forni,Alberto Pilotto
Annals of the New York Academy of Sciences. 2016;
[Pubmed]  [Google Scholar] [DOI]
13 A complicated disease: what can be done to manage thalassemia major more effectively?
Raffaella Origa,Alessandro Baldan,Maria Marsella,Caterina Borgna-Pignatti
Expert Review of Hematology. 2015; 8(6): 851
[Pubmed]  [Google Scholar] [DOI]
14 Denosumab for the treatment of osteoporosis
Sarah Zaheer,Meryl LeBoff,E Michael Lewiecki
Expert Opinion on Drug Metabolism & Toxicology. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article